Featured Research

from universities, journals, and other organizations

UNC Researchers Testing First In New Class Of AIDS Drugs

Date:
January 29, 1999
Source:
University Of North Carolina At Chapel Hill
Summary:
AIDS investigators at the University of North Carolina at Chapel Hill are testing the first of a new class of drugs that attacks HIV before it enters the cell and may prove effective for patients with drug-resistant HIV.

CHAPEL HILL, N.C. -- AIDS investigators at the University of North Carolina at Chapel Hill are testing the first of a new class of drugs that attacks HIV before it enters the cell and may prove effective for patients with drug-resistant HIV.

Related Articles


The fusion inhibitor, known as T-20, prevents HIV from fusing with the cell surface membrane. Thus, T-20 attacks HIV in an entirely different way than the most potent HIV agents now in use.

"HIV resistant to the currently available medications would not be expected to be resistant to this drug because of its unique action," says Dr. Joseph Eron, associate professor of medicine at the UNC-CH School of Medicine.

On Feb. 4, Eron will present detailed findings of the study at the Sixth Conference on Retroviruses and Opportunistic Infections in Chicago.

Eron is a principal investigator for this multi-center study begun in August and sponsored by Durham-based Trimeris, Inc., maker of T-20. He says the results are impressive, "particularly when one considers the population that enrolled in this clinical trial is extremely difficult to treat."

The infectious disease specialist notes that the average number of anti-HIV medications taken by the 78 HIV-infected patients prior to the Trimeris Phase II Clinical Trial was nine. None of the agents, including an average of three protease inhibitors per patient, had proven effective in these patients over the long-term. Additionally daunting was the patients' very high average baseline viral load -- the concentration of HIV particles per milliliter of blood. But according to Eron, patients in the new trial taking higher T-20 doses showed up to 90 percent reductions in viral load without major side effects.

In the trial, T-20 was given for 28 days either by continuous subcutaneous infusion or simply by injecting it subcutaneously (much like insulin is administered in diabetes). T-20 was also given either as part of an anti-retroviral drug "cocktail" or as the sole drug.

Eron says the new results definitively show that injection can be an alternative to infusion. Targeted blood levels of T-20 were achieved both through infusion and with twice-daily injections.

"This finding is important because twice-daily injection is far more convenient for patients than a continuous subcutaneous infusion pump," Eron explains.

"I think the study is extremely important because it is a clear demonstration of anti-retroviral effects with an agent that is completely novel, one that works by a different mechanism of action than currently available therapies," Eron says.

Results of this and subsequent T-20 investigations by Trimeris will be aimed at meeting rigorous Food and Drug Administration scrutiny to obtain approval for the drug.

"This particular trial was aimed at finding the correct dose and to show 'proof of principle' that the drug could be administered in a relatively convenient way," Eron says. "The trial lets me and others test a new drug on HIV patients who have failed lots of drugs and provides important information that will allow us to go on and study T-20 in combination with other HIV medications for longer durations."


Story Source:

The above story is based on materials provided by University Of North Carolina At Chapel Hill. Note: Materials may be edited for content and length.


Cite This Page:

University Of North Carolina At Chapel Hill. "UNC Researchers Testing First In New Class Of AIDS Drugs." ScienceDaily. ScienceDaily, 29 January 1999. <www.sciencedaily.com/releases/1999/01/990129074334.htm>.
University Of North Carolina At Chapel Hill. (1999, January 29). UNC Researchers Testing First In New Class Of AIDS Drugs. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/1999/01/990129074334.htm
University Of North Carolina At Chapel Hill. "UNC Researchers Testing First In New Class Of AIDS Drugs." ScienceDaily. www.sciencedaily.com/releases/1999/01/990129074334.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins